Apoptosis: a mechanism of acute and chronic liver injury

被引:403
作者
Guicciardi, ME [1 ]
Gores, GJ [1 ]
机构
[1] Mayo Clin, Coll Med, Rochester, MN 55905 USA
关键词
D O I
10.1136/gut.2004.053850
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Apoptosis represents the physiological way to eliminate excessive cells during embryogenesis and tissue remodelling. Under these conditions, apoptosis occurs in a controlled environment where dying cells are promptly removed by phagocytosis and replaced by new cells generated by mitosis. Apoptosis, however, is also an essential feature of a wide variety of acute and chronic diseases, including liver diseases. Imbalance between cell proliferation and death always leads to loss of tissue homeostasis and onset of various diseases. Excessive apoptosis has, indeed, been identified in acute and chronic viral hepatitis, alcoholic and non-alcoholic hepatitis, cholestatic liver disease, Wilson's disease, and graft versus host disease (GVHD). Sustained apoptosis has also been linked with the development of hepatic fibrosis. In contrast, insufficient apoptosis has been associated with development and progression of tumours of the liver and the biliary tree. Thus identification of target molecules involved in apoptosis may offer new options for pharmacological and/or gene mediated therapies for patients with liver diseases (fig 5).
引用
收藏
页码:1024 / 1033
页数:10
相关论文
共 130 条
  • [41] Bile acid-mediated hepatocyte apoptosis and cholestatic liver disease
    Guicciardi, ME
    Gores, GJ
    [J]. DIGESTIVE AND LIVER DISEASE, 2002, 34 (06) : 387 - 392
  • [42] Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
    Hahne, M
    Rimoldi, D
    Schroter, M
    Romero, P
    Schreier, M
    French, LE
    Schneider, P
    Bornand, T
    Fontana, A
    Lienard, D
    Cerottini, JC
    Tschopp, J
    [J]. SCIENCE, 1996, 274 (5291) : 1363 - 1366
  • [43] CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE
    HARRIS, CC
    HOLLSTEIN, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (18) : 1318 - 1327
  • [44] Higaki K, 1996, AM J PATHOL, V149, P429
  • [45] Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity
    Higuchi, H
    Bronk, SF
    Taniai, M
    Canbay, A
    Gores, GJ
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (02) : 461 - 467
  • [46] The bile acid glycochenodeoxycholate induces TRAIL-receptor 2/DR5 expression and apoptosis
    Higuchi, H
    Bronk, SF
    Takikawa, Y
    Werneburg, N
    Takimoto, R
    El-Deiry, W
    Gores, GJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) : 38610 - 38618
  • [47] Higuchi H, 2001, J PHARMACOL EXP THER, V299, P866
  • [48] HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606
  • [49] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    [J]. SCIENCE, 1991, 253 (5015) : 49 - 53
  • [50] Horowitz J, 1999, CURR OPIN MOL THER, V1, P500